| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TNF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$42.00 |
| 52 Week Low | US$1.62 |
| Beta | 2.7 |
| 11 Month Change | -2.78% |
| 3 Month Change | -24.89% |
| 1 Year Change | -95.61% |
| 33 Year Change | -98.92% |
| 5 Year Change | n/a |
| Change since IPO | -98.82% |
Recent News & Updates
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01
We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29Shareholder Returns
| TNFA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.8% | 5.6% | 2.6% |
| 1Y | -95.6% | 13.7% | 17.3% |
Return vs Industry: TNFA underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: TNFA underperformed the US Market which returned 17.3% over the past year.
Price Volatility
| TNFA volatility | |
|---|---|
| TNFA Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TNFA's share price has been volatile over the past 3 months.
Volatility Over Time: TNFA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 6 | n/a | tnfpharma.com |
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
TNF Pharmaceuticals, Inc. Fundamentals Summary
| TNFA fundamental statistics | |
|---|---|
| Market cap | US$4.15m |
| Earnings (TTM) | -US$17.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs TNFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNFA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.55m |
| Earnings | -US$17.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TNFA perform over the long term?
See historical performance and comparison